Changjiang Securities·2025-11-11 10:12Investment Rating - The report maintains a "Buy" rating for China Life Insurance [2][8]. Core Views - The long-term logic of the insurance industry is the improvement of profitability, while the short-term focus is on market beta. The recent performance demonstrates the insurance sector's resilience and profit release capability during favorable equity market conditions, indicating a potential revaluation of the industry. China Life, as a pure life insurance company, possesses top-tier sensitivity and elasticity within the industry, making it a quality beta asset for allocation. The current valuation stands at 0.80 times PEV [2][12]. Summary by Sections Financial Performance - In the first three quarters of 2025, China Life achieved a net profit attributable to shareholders of 167.8 billion yuan, representing a year-on-year increase of 60.5%. The new business value also grew by 41.8% year-on-year [6][12]. Investment Returns - The company reported a total investment return rate of 6.42%, an increase of 104 basis points year-on-year, with total investment income reaching 368.55 billion yuan, up 41% year-on-year [12]. Liability Management - New business value increased by 41.8% year-on-year, driven by a 10.4% rise in new single premiums. The retention rate remains low at 0.74%, indicating stable liability quality [12]. Workforce and Operational Efficiency - As of the end of Q3 2025, the individual insurance workforce stood at 607,000, showing stability compared to mid-2025. The quality of the workforce has also improved, with higher retention rates and enhanced operational efficiency [12]. Investment Recommendations - The report suggests that China Life is a high-elasticity asset. The insurance sector is expected to see improved profitability in the long term, with a focus on market beta in the short term. The company is positioned for potential valuation reappraisal, maintaining a "Buy" rating [12].